---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-25-000003"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T10:34:04.167933+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pulmonx reports record Q4 revenue $23.8M (+23% YoY) and FY2024 revenue $83.8M (+22%); FY2025 guidance $96-98M

## Summary
- Record Q4 2024 worldwide revenue $23.8M, up 23% YoY; U.S. revenue $15.9M (+16%), international $7.9M (+42%).
- Full year 2024 revenue $83.8M, up 22% YoY; net loss $56.4M ($1.44/shr) narrowed from $60.8M ($1.60/shr) in 2023.
- Adjusted EBITDA loss improved to $31.3M in 2024 from $39.0M in 2023; gross margin stable at 74%.
- Cash and equivalents $101.5M at year-end 2024; added 11 new U.S. Zephyr Valve treatment centers in Q4.
- FY2025 revenue guidance $96-98M (15-17% growth); operating expenses $133-135M including $22M stock comp.

## SEC filing metadata
- accession: 0001127537-25-000003
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753725000003/0001127537-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753725000003/lung-20250219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-25-000003
- JSON: https://secwatch.observer/filing/0001127537-25-000003.json
- Plain text: https://secwatch.observer/filing/0001127537-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.